Principal Investigator
Jonathan Trent
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220946
Clinical Trial Summary
An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study with AL3818 (A Compassionate Use Trial)
Phase
N/A
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
305-243-2647